Ovarian Cancer Data Give Corcept’s Shares a Bounce After Year-End CRL Drop

Why It Matters

The OS success revives Corcept’s growth prospects and could restore its valuation, while demonstrating the therapeutic potential of GPCR antagonists in hard‑to‑treat ovarian cancer.

Key Takeaways

• Phase III trial met overall survival endpoint
• Relacorilant targets platinum‑resistant ovarian cancer
• Shares rose after previous 50% year‑end drop
• Success may offset earlier hypercortisolism CRL impact

Pulse Analysis

Corcept Therapeutics' relacorilant, a selective glucocorticoid receptor antagonist, entered a pivotal Phase III trial in patients with platinum‑resistant ovarian cancer last year. The study enrolled 420 participants across 65 sites and evaluated overall survival as the primary endpoint. In the final analysis, relacorilant extended median survival by 4.2 months compared with standard chemotherapy, achieving statistical significance at the pre‑specified alpha level. These results mark the first time a GPCR‑targeted small molecule has demonstrated a clear survival benefit in this indication. The safety profile remained comparable to control, with no new signals.

The positive data triggered an immediate rally, pushing Corcept's share price up 12% in after‑hours trading and erasing a portion of the 50% plunge caused by the year‑end complete response letter on its hypercortisolism program. Market analysts now project a revised 12‑month price target of $85, up from $55, reflecting renewed confidence in the company's pipeline diversification. However, the lingering regulatory shadow from the CRL means the firm must still secure FDA approval for relacorilant in ovarian cancer before the upside can be fully realized. The company also announced plans to file a supplemental NDA by Q3 2026.

Beyond Corcept, the trial outcome underscores the growing relevance of glucocorticoid receptor modulation in oncology, a pathway previously explored mainly for endocrine disorders. If the FDA grants approval, relacorilant could join a limited class of oral agents that address both hormone‑driven and chemotherapy‑resistant tumors, potentially opening combination strategies with PARP inhibitors or immunotherapies. Investors and competitors alike will watch the filing timeline closely, as a successful launch could reshape treatment algorithms and stimulate further investment in GPCR‑focused drug discovery. Such data could accelerate partnerships with larger oncology players seeking to broaden their portfolios.